Essa Pharma Q4 2024 Earnings Report

ESSA Pharma reported financial results for the fourth quarter and fiscal year ended September 30, 2024, and initiated a process to explore strategic options.

Key Takeaways

ESSA Pharma announced the termination of its clinical development of masofaniten and is evaluating strategic options to maximize shareholder value. The company reported financial results for Q4 and the fiscal year ended September 30, 2024.

Terminated clinical development of masofaniten based on interim analysis.

Evaluating strategic options to maximize shareholder value.

Reported financial results for the fourth quarter and fiscal year ended September 30, 2024.

Withdrew the related IND and CTAs for masofaniten.

Previous year: -$0.12

+16.7%

Gross Profit

-$22.8K

Previous year: -$27.1K

Previous year: -$4.53M

Essa Pharma

Essa Pharma

Unlock previous datapoints

Upgrade

Forward Guidance

ESSA Pharma is currently evaluating and reviewing strategic options focused on maximizing shareholder value and look forward to providing further updates in the near future.

Historical Earnings Impact

Analyze how earnings announcements historically affect stock price performance

Avg. Return Before/After Earnings

Loading earnings performance data...

Loading earnings reaction data...

Company Overview

Full financial data and analysis

View Essa Pharma

Products

Get in Touch

Resources

Essa Pharma Q4 2024 Earnings Report

Key Takeaways

Essa Pharma

Essa Pharma

Forward Guidance

Historical Earnings Impact

Avg. Return Before/After Earnings

Company Overview